These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32399093)

  • 1. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.
    Katsiki N; Banach M; Mikhailidis DP
    Arch Med Sci; 2020; 16(3):485-489. PubMed ID: 32399093
    [No Abstract]   [Full Text] [Related]  

  • 2. Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?
    Park S; Lee HY; Cho EJ; Sung KC; Kim J; Kim DH; Ihm SH; Kim KI; Sohn IS; Chung WJ; Kim HC; Ryu SK; Pyun WB; Shin J;
    Clin Hypertens; 2020; 26():11. PubMed ID: 32391169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The renin angiotensin aldosterone system and COVID-19.
    Alsufyani HA; Docherty JR
    Saudi Pharm J; 2020 Aug; 28(8):977-984. PubMed ID: 32788834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First orally active DRI Aliskiren--a new prospect in management of hypertension and beyond.
    Sawhney JP
    Indian Heart J; 2010; 62(1):49-56. PubMed ID: 21180035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study.
    Villard O; Morquin D; Molinari N; Raingeard I; Nagot N; Cristol JP; Jung B; Roubille C; Foulongne V; Fesler P; Lamure S; Taourel P; Konate A; Maria ATJ; Makinson A; Bertchansky I; Larcher R; Klouche K; Le Moing V; Renard E; Guilpain P
    J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32708205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of laboratory disturbance risk when adding low-dose cotrimoxazole for PJP prophylaxis to regimens of high-grade glioma patients taking RAAS inhibitors.
    Coppens R; Yang J; Ghosh S; Gill J; Chambers C; Easaw JC
    J Oncol Pharm Pract; 2019 Sep; 25(6):1366-1373. PubMed ID: 30124122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Vasopressin for Septic Shock in Patients on Chronic Renin-Angiotensin-Aldosterone System Inhibitors.
    Erwin BL; Denaburg MA; Barker AB; McArdle PJ; Windham ST; Morgan CJ
    Crit Care Med; 2017 Dec; 45(12):e1226-e1232. PubMed ID: 28991825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The renin-angiotensin-aldosterone system and heart failure.
    Sayer G; Bhat G
    Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval.
    Zannad F; Rossignol P; Stough WG; Epstein M; Alonso Garcia Mde L; Bakris GL; Butler J; Kosiborod M; Berman L; Mebazaa A; Rasmussen HS; Ruilope LM; Stockbridge N; Thompson A; Wittes J; Pitt B
    Int J Cardiol; 2016 Aug; 216():46-51. PubMed ID: 27140336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study.
    Lee AF; MacFadyen RJ; Struthers AD
    Eur J Heart Fail; 1999 Dec; 1(4):401-6. PubMed ID: 10937954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
    J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease.
    Brewster UC; Perazella MA
    Am J Med; 2004 Feb; 116(4):263-72. PubMed ID: 14969655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of long-term treatment of arterial hypertension with Ca antagonists on the renin-angiotensin-aldosterone system in diabetics. Hyporeninemic hypoaldosteronism].
    Hrnciar J; Jakubíková K; Hrnciarová M; Kreze A; Chamulová M
    Vnitr Lek; 1995 Oct; 41(10):661-6. PubMed ID: 8578695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
    van Diepen S; Reynolds HR; Stebbins A; Lopes RD; Džavík V; Ruzyllo W; Geppert A; Widimsky P; Ohman EM; Parrillo JE; Dauerman HL; Baran DA; Hochman JS; Alexander JH
    Crit Care Med; 2014 Feb; 42(2):281-8. PubMed ID: 23982033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences?
    Klotz S; Burkhoff D; Garrelds IM; Boomsma F; Danser AH
    Eur Heart J; 2009 Apr; 30(7):805-12. PubMed ID: 19223317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system.
    Benck U; Haeckel S; Clorius JH; van der Woude FJ
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):58-67. PubMed ID: 17699388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.
    Petrykiv SI; Laverman GD; Persson F; Vogt L; Rossing P; de Borst MH; Gansevoort RT; de Zeeuw D; Heerspink HJL
    Clin J Am Soc Nephrol; 2017 Nov; 12(11):1804-1813. PubMed ID: 29021336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.